2025
|
Invention
|
Enhanced immune effector cells and use thereof.
Provided are methods and compositions for obtain... |
2024
|
Invention
|
Ipsc-derived t cells for solid tumor treatment. Provided are methods and compositions for use in ... |
|
Invention
|
Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors.
Provided ... |
|
Invention
|
Compositions and methods for muscle disorders. The invention discloses approaches to correct DUX-... |
|
Invention
|
Ipsc-derived effector cells for autoimmune disease treatment. Provided are methods and compositio... |
|
Invention
|
Liver detargeted capsids. The present invention provides novel capsid variants for viral vectors ... |
|
Invention
|
Solid tumor targeting backbone promoting effector cell differentiation and function. Provided are... |
|
Invention
|
Aav gene therapy approach for treating lgmd2b/dysferlinopathy. This disclosure relates to composi... |
|
Invention
|
Ipsc-derived nk cell for lymphoma treatment. Provided are methods and compositions for use in can... |
|
Invention
|
Compositions and methods for immune cell modulation in adoptive immunotherapies.
Compounds that ... |
|
Invention
|
Muscle targeted capsids. The present invention provides novel capsid variants for viral vectors t... |
2023
|
Invention
|
Ipsc-derived nk cell targeting mica/b for solid tumor treatment. Provided are methods and composi... |
|
Invention
|
Composition and methods for inducing myeloid suppressive cells and use thereof.
Compositions and... |
|
Invention
|
Off-the-shelf therapeutic cells with multiplex genomic engineering for targeting cd79b. . Provide... |
|
Invention
|
Off-the-shelf therapeutic cells with multiplex genomic engineering for targeting gprc5d. Provided... |
|
Invention
|
Off-the-shelf therapeutic cells with multiplex genomic engineering for targeting kallikrein-2. Pr... |
|
P/S
|
Stem cells for medical purposes; therapeutic cell preparation for the treatment of auto-immune di... |
|
Invention
|
Methods and compositions for inducing hematopoietic cell differentiation. In various aspects, the... |
|
Invention
|
Methods and compositions for inducing hematopoietic cell differentiation |
|
Invention
|
Chimeric antigen receptor for tumor targeting. Provided are chimeric antigen receptors (CAR) spec... |
|
Invention
|
Cells having solid tumor targeting backbone and use thereof. Provided are methods and composition... |
|
Invention
|
Enhancing effector cell durability and efficacy in adoptive cell therapies. Provided are methods ... |
|
Invention
|
Enhancing effector cell durability and efficacy in adoptive cell therapies |
|
Invention
|
Compositions for treating xlmtm. The present invention provides a novel muscle-tropic viral vecto... |
|
Invention
|
Stealth strategy engaging immune recognition pathways for use in allogeneic cell therapies. Provi... |
|
Invention
|
Compositions and methods for muscle disorders. The invention discloses approaches to reduce expre... |
|
Invention
|
Methods and compositions for inducing hematopoietic cell differentiation.
The invention provides... |
2022
|
Invention
|
Engineered effector cells and methods of enhancing ubiquitous targeting of solid tumors.
Provide... |
|
Invention
|
Engineered effector cells for trafficking of allogeneic cell therapies in solid tumors.
Provided... |
|
Invention
|
Engineered effector cells for trafficking of allogeneic cell therapies in solid tumors. Provided ... |
|
Invention
|
Engineered effector cells and methods of enhancing ubiquitous targeting of solid tumors. Provided... |
|
P/S
|
Therapeutic cell preparations based on NK cells (natural killer cells) for the treatment of cance... |
|
Invention
|
Off-the-shelf ipsc-derived car-nk cell as monotherapy and in combination with antibody.
Provided... |
|
Invention
|
Protected effector cells and use thereof for allogeneic adoptive cell therapies.
Provided are me... |
2021
|
Invention
|
Off-the-shelf ipsc-derived nk cell therapy for hematological cancer treatment.
Provided are meth... |
|
Invention
|
Engineered ipsc and immune effector cells for heterogenous tumor control.
Provided are methods a... |
|
Invention
|
Engineered ipsc and persistent immune effector cells.
Provided are methods and compositions for ... |
|
Invention
|
Multiplexed engineered ipscs and immune effector cells targeting solid tumors.
Provided are meth... |
|
Invention
|
Engineered ipsc and armed immune effector cells.
Provided are methods and compositions for obtai... |
|
Invention
|
Improved reprogramming, maintenance and preservation for induced pluripotent stem cells.
Provide... |
|
Invention
|
Combining ipsc derived effector cell types for immunotherapy use. Provided are methods and compos... |
|
P/S
|
Cells for medical purposes; therapeutic preparation for the treatment of disease and immune disor... |
2020
|
Invention
|
Enhanced chimeric antigen receptor for immune effector cell engineering and use thereof.
Provide... |
|
Invention
|
Vial rack |
2017
|
P/S
|
Cells and pharmaceutical preparations for the treatment of diseases, namely hematopoietic cells f... |
|
P/S
|
Cells for medical purposes; therapeutic preparation for the
treatment of disease and immune diso... |
|
P/S
|
Cells and pharmaceutical preparations for the treatment of
diseases; bio-engineered component fo... |
2016
|
P/S
|
Reagents for research, drug discovery and development, and clinical laboratory use Pharmaceutical... |
|
P/S
|
Medical and clinical research and development for others in the field of stem cells; consulting s... |
|
P/S
|
Pharmaceutical preparations and therapeutic agents to modulate cell function or cell fate; reagen... |
2013
|
P/S
|
Pharmaceutical preparations and therapeutic agents to modulate stem cell pathways to promote heal... |
2012
|
P/S
|
Stem cells for medical purposes; therapeutic preparation for
the treatment of diseases. |
2010
|
P/S
|
medical and clinical research and development for others in the field of stem cells; consulting s... |
2009
|
P/S
|
Reagents for research, drug discovery and development in the field of stem cells and small molecu... |
|
P/S
|
Pharmaceutical preparations and therapeutic agents;
pharmaceutical preparations and therapeutic ... |
|
P/S
|
pharmaceutical preparations and therapeutic agents to modulate cell fate; reagents for research, ... |